Skip to main content
padlock icon - secure page this page is secure

An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme

Buy Article:

$52.00 + tax (Refund Policy)

Pellettieri L, H-Stenstam B, Rezaei A, Giusti V, Sköld K. An investigation of boron neutron capture therapy for recurrent glioblastoma multiforme.

Acta Neurol Scand: DOI: 10.1111/j.1600-0404.2007.00924.x.

© 2007 Hammercap Medical AB Journal compilation © 2007 Blackwell Munksgaard. Objectives – 

To explore the use of boron neutron capture therapy (BNCT) for patients with glioblastoma multiforme (GBM), recurring after surgery and conventional radiotherapy (photon radiotherapy). Materials and methods – 

Boron uptake in recurrent GBM was measured for four patients. Twelve patients were subsequently treated by BNCT with boronophenylalanine-fructose (900 mg/kg body weight), administered by intravenous infusion for 6 h. Results – 

Median survival time from initial diagnosis was 22.2 months. Comparison with other BNCT studies indicates a clinical advantage of the prolonged infusion. BNCT was well tolerated and quality of life remained stable until tumor progression for all 12 patients. No correlation was found between survival times and minimum tumor dose and number of radiation fields. Conclusions – 

Boron neutron capture therapy, with the prolonged procedure for infusion, is at least as effective as other radiation therapies for recurrent GBM and is delivered in one treatment session, with low radiation dose to the healthy brain. Survival from diagnosis compares favorably with that obtained with conventional radiotherapy plus concomitant and adjuvant temozolomide (TMZ) and survival from recurrence compares favorably with that obtained with TMZ at first relapse. The results of the present investigation are encouraging and should be confirmed in a randomized trial.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: boron neutron capture therapy; boronophenylalanine; recurrent glioblastoma; survival; toxicity

Document Type: Research Article

Affiliations: 1: Nyköping Hospital, County of Sormland, Sweden 2: Hammercap Medical AB (previously Studsvik Medical AB), Stockholm, Sweden

Publication date: March 1, 2008

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more